Arévalo MFG, Badia FJJ

Language: Spanish
References: 10
Page: 54-55
PDF size: 106.73 Kb.

ABSTRACT

Vasculitis is the inflammation and destruction of the walls of the blood vessels that leads to occlusion or the formation of aneurysms, with the resulting ischemic-hemorrhagic changes. The involvement of central nervous system vessels darkens the prognosis and can be serious. Being a multi-causal disease with similar clinical and imaging manifestations, the differential diagnosis is a challenge. Vasculitis can be primary, associated with connective tissue diseases, infections, neoplasms and drugs. We present a case of cerebral vasculitis in a patient with rheumatoid arthritis secondary to a biological anti-FNT alpha medication that progressed satisfactorily to treatment with corticosteroids and immunosuppressive drugs.

REFERENCES

1. Guillevin L. Clasificación de las vasculitis sistémicas. EMC-Tratado de Medicina. 2017; 21 (1): 1-5.

2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al. 2012 International Chapel Hill consensus conference nomenclature of vasculitis. Arthritis Rheum. 2013; 65 (1): 1-11.

3. Ramos-Casals M, Brito-Zerón P, Munoz S. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86 (4): 242-251.

4. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011; 41 (2): 256-264.

5. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010; 146 (7): 780-784.

6. Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients: a systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 2008; 26 (3 suppl 49): S23-S29.

7. Navarro R, Dauden E. Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico. Actas Dermosifiliogr. 2014; 105 (8): 752-761.

8. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patient following treatment with infliximab a monoclonal antibody to tumor necrosis factor alpha: findings in open label and randomized placebo-controlled trials. Arthritis Rheum. 2000; 43 (11): 2383-2390.

9. Ozkul A, Yilmaz A, Akyol A, Kiylioglu N. Cerebral vasculitis as a major manifestation of rheumatoid arthritis. Acta Clin Belg. 2015; 70 (5): 359-363.

10. Salvarani C, Pipitone N, Hunder GG. Management of primary and secondary central nervous system vasculitis. Curr Opin Rheumatol. 2016; 28 (1): 21-28.